We have shown here that LAU-0901 (PAF receptor antagonist), ELV (a novel lipid mediator), Avastin (monoclonal antibody against VEGF), and their combination improved survival and reduced tumor volume and growth in the experimental GBM model. The gene discussed is VEGFA; the disease is neoplasm.